Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Respiratory SYNcytial Virus antivirALs: A Phase 2 Multi-centre Adaptive Randomised Platform Trial For the Assessment of Antiviral Pharmacodynamics in aCute Symptomatic RSV Infection (ARSYNAL-FC)

NCT06488300 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT06488300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06488300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Respiratory SYNcytial Virus antivirALs: A Phase 2 Multi-centre Adaptive Randomised Platform Trial For the Assessment of Antiviral Pharmacodynamics in aCute Symptomatic RSV Infection (ARSYNAL-FC)
Lead sponsor
University of Oxford
Phase
Phase 2
Overall status
Recruiting
Start date
July 25, 2024
Completion date
January 1, 2027
Enrollment
1,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus, respiratory syncytial virus, human